seralutinib   Click here for help

GtoPdb Ligand ID: 10618

Synonyms: GB-002 | Gb002 | PK-10571 | PK10571 | structure 2a [WO2014110200A1]
Compound class: Synthetic organic
Comment: Seralutinib (PK10571; Structure 2a; GB002) is a small molecule inhibitor of platelet-derived growth factor receptors A and B (PDGFRα, PDGFRβ; receptor tyrosine kinases) [1]. It was developed to target the PDGF pathway as a therepuetic modality for the treatment of pulmonary arterial hypertension (PAH). PK10571 is being progressed for PAH by Gossamer Bio in collaboration with Pulmokine. Inhibition of PDGFRα/β is predicted to stop and/or reverse the vascular remodeling associated with PAH and thereby improve cardiopulmonary hemodynamics in these patients.

seralutinib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 98.26
Molecular weight 469.21
XLogP 3.66
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COc1cc(ccc1OC)c1cncc(n1)NC(c1cccc(c1)NC(=O)c1cncc(c1)C)C
Isomeric SMILES COc1cc(ccc1OC)c1cncc(n1)N[C@H](c1cccc(c1)NC(=O)c1cncc(c1)C)C
InChI InChI=1S/C27H27N5O3/c1-17-10-21(14-28-13-17)27(33)31-22-7-5-6-19(11-22)18(2)30-26-16-29-15-23(32-26)20-8-9-24(34-3)25(12-20)35-4/h5-16,18H,1-4H3,(H,30,32)(H,31,33)/t18-/m0/s1
InChI Key JHJNPOSPVGRIAN-SFHVURJKSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
PK10571 (GB002) is in Phase 1 development in patients with WHO Group I PAH (NCT03926793). It is being admimistered as an inhalation powder to restrict systemic exposure and side-effects.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03926793 Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension Phase 1 Interventional Gossamer Bio Inc.